🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic ...
Status
Unknown
Location
Multiple Locations
Start Date
2018-11-30
Trial ID
NCT03750916
Treatments Being Tested
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic ...
Status
Unknown
Location
Shandong Cancer Hospital
Start Date
2020-11-04
Trial ID
NCT04619563
Treatments Being Tested
This is a randomized, controlled, open-label, multicenter study to evaluate...
Status
Unknown
Location
The First Affiliated Hospital of Anhui Medical University
Start Date
2020-05-20
Trial ID
NCT04385550
Treatments Being Tested
Anlotinib is a multi-target receptor tyrosine kinase inhibitor under domest...
Status
Unknown
Location
Shandong Cancer Hospital
Start Date
2020-10-08
Trial ID
NCT04619537
Treatments Being Tested
Anlotinib which has shown an affirmatory efficacy in ALTER0303 controlled t...
Status
Unknown
Location
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology,
Start Date
2019-03-01
Trial ID
NCT03799601
Treatments Being Tested
This clinical study plans to enroll 69 endometrial cancer patients and 5-10...
Status
Terminated
Location
Sun Yat-sen Memorial Hospital
Start Date
2022-08-26
Trial ID
NCT05481645
anlotinib was added to TP inductive chemotherapy and definitive chemoradiat...
Status
Unknown
Location
Zhejiang Cancer Hospital
Start Date
2021-01-01
Trial ID
NCT05232552
Treatments Being Tested
Anlotinib hydrochloride is a multi-target antiangiogenic drug. It was recom...
Status
Unknown
Location
Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine
Start Date
2019-12-30
Trial ID
NCT04757779
Treatments Being Tested
This study is conducted to explore the safety and efficacy of anlotinib, a ...
Status
Unknown
Location
People's hospital of deyang city
Start Date
2018-10-16
Trial ID
NCT03703596
Treatments Being Tested
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic ...
Status
Unknown
Location
Multiple Locations
Start Date
2018-11-15
Trial ID
NCT03735264
Treatments Being Tested